Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line September 9, 2026
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors September 9, 2026
China’s Simnova Bags USD59.5 Million in New Funding to Advance Off-the-Shelf Cell Therapies September 9, 2026
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors September 9, 2026
Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines September 9, 2026
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Gen ADCs Built on DualityBio’s DUPAC Novel-Payload Platform September 2, 2026
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer September 2, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer August 25, 2026
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline August 25, 2026
AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in LBCL August 25, 2026
Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors August 25, 2026
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline August 25, 2026
TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement aimed at Ph 2 development of NOX-A12 August 25, 2026
Vepdegestrant Now Available for U.S. Patients With ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer August 20, 2026
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China August 11, 2026
Evexta Bio and Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced/Metastatic Breast Cancer August 11, 2026
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand August 11, 2026
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma August 11, 2026
Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure August 5, 2026
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC August 5, 2026
Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Gen ADC Manufacturing Technologies August 5, 2026
